MedPath

NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

593

Active:7
Completed:473

Trial Phases

6 Phases

Early Phase 1:10
Phase 1:72
Phase 2:84
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (212 trials with phase data)• Click on a phase to view related trials

Phase 2
84 (39.6%)
Phase 1
72 (34.0%)
Not Applicable
24 (11.3%)
Phase 3
17 (8.0%)
Early Phase 1
10 (4.7%)
Phase 4
5 (2.4%)

Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia

Recruiting
Conditions
Ebola
Post-Acute Ebola Syndrome
First Posted Date
2025-02-06
Last Posted Date
2025-07-11
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
410
Registration Number
NCT06811129
Locations
🇱🇷

John F. Kennedy Medical Center, Monrovia, Liberia

Predicting Future Errors During Skill Performance

Recruiting
Conditions
Healthy
First Posted Date
2024-11-27
Last Posted Date
2025-07-11
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
40
Registration Number
NCT06707207
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic Syndromes

Recruiting
Conditions
Myasthenic Syndromes, Congenital
First Posted Date
2024-10-08
Last Posted Date
2025-05-16
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
75
Registration Number
NCT06630650
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke

Recruiting
Conditions
Stroke
Brain Disease
Vascular Diseases
Cerebrovascular Disorder
First Posted Date
2024-09-27
Last Posted Date
2025-07-11
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
450
Registration Number
NCT06615973
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

Recruiting
Conditions
PASC Post Acute Sequelae of COVID-19
First Posted Date
2024-08-29
Last Posted Date
2025-06-13
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
12
Registration Number
NCT06577467
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 119
  • Next

News

Uric Acid Shows Promise as Novel Add-On Therapy for Ischemic Stroke in NIH-Funded Study

NIH-funded preclinical research demonstrates that uric acid treatment significantly improved sensorimotor function and survival rates in rodents 30 days after ischemic stroke.

UVA Launches $30M Trial to Test Ketamine for Life-Threatening Seizures

The University of Virginia has secured a $9.3 million NIH grant as initial funding for a $30 million clinical trial investigating ketamine's potential in treating status epilepticus, a life-threatening seizure condition.

Newer Epilepsy Medications During Pregnancy Show No Impact on Children's Neurodevelopment at Age 6

A recent study indicates that newer anti-seizure medications, like lamotrigine and levetiracetam, pose no significant risk to children's language development when taken during pregnancy.

NIH Collaboratory Adds APA-SM Trial to Evaluate Acupressure for Chronic Pain Management

The NIH Pragmatic Trials Collaboratory welcomes the APA-SM trial, focusing on personalized auricular point acupressure for chronic pain self-management in rural areas.

© Copyright 2025. All Rights Reserved by MedPath